Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Leases: 2012-2023

  • Ascendis Pharma A's Current Leases rose 8.52% to $15.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $15.3 million, marking a year-over-year increase of 8.52%. This contributed to the annual value of $15.3 million for FY2023, which is 8.52% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Current Leases of $15.3 million as of Q4 2023, which was up 8.52% from $14.1 million recorded in Q4 2022.
  • In the past 5 years, Ascendis Pharma A's Current Leases registered a high of $15.3 million during Q4 2023, and its lowest value of $6.5 million during Q4 2019.
  • Moreover, its 3-year median value for Current Leases was $14.1 million (2022), whereas its average is $12.5 million.
  • Per our database at Business Quant, Ascendis Pharma A's Current Leases spiked by 676.21% in 2019 and then decreased by 2.15% in 2021.
  • Over the past 5 years, Ascendis Pharma A's Current Leases (Quarterly) stood at $6.5 million in 2019, then rose by 25.25% to $8.2 million in 2020, then declined by 2.15% to $8.0 million in 2021, then surged by 75.95% to $14.1 million in 2022, then rose by 8.52% to $15.3 million in 2023.
  • Its Current Leases stands at $15.3 million for Q4 2023, versus $14.1 million for Q4 2022 and $8.0 million for Q4 2021.